Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6964)
All Articles published online
|
Publishing Process of This Article
|
Nov 21, 2016 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Hlaing NKT, Banerjee D, Mitrani R, Arker SH, Win KS, Tun NL, Thant Z, Win KM, Reddy KR. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country. World J Gastroenterol 2016; 22(43): 9613-9622 [PMID: 27920482 DOI: 10.3748/wjg.v22.i43.9613] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v22/i43/9613.htm |
| Number | Citing Articles |
| 1 |
Aung H. Bwa, Gayatri Nangia, Si T.S. Win, Soe T. Maung, Khin A.W. Han, Su S. Htar, Lei Y. Wine, Wint W. Ko, Moe P. Oo, Naomi K.T. Hlaing, Julia Palecki, Bao L. Loza, Khin M. Win, Rajender Reddy. Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience. Journal of Clinical and Experimental Hepatology 2019; 9(3): 283 doi: 10.1016/j.jceh.2018.12.001
|
| 2 |
Rosario Sabariegos, Ana María Ortega-Prieto, Luis Díaz-Martínez, Ana Grande-Pérez, Carlos García Crespo, Isabel Gallego, Ana I. de Ávila, Laura Albentosa-González, María Eugenia Soria, Pablo Gastaminza, Esteban Domingo, Celia Perales, Antonio Mas, Marco Vignuzzi. Guanosine inhibits hepatitis C virus replication and increases indel frequencies, associated with altered intracellular nucleotide pools. PLOS Pathogens 2022; 18(1): e1010210 doi: 10.1371/journal.ppat.1010210
|
| 3 |
Mohamed F. Montasser, Samy Zaky, Mohamed Salaheldin, Dina Johar, Abdelrahman Ibrahim Abushouk, Fathiya El-Raey, Muneer Al-Husseini, Elsayed G. Mohammed. Fib-4 Predicts Early Hematological Adverse Events Induced by Interferon-Based Triple Therapy in Chronic Hepatitis C Virus Patients. Journal of Interferon & Cytokine Research 2019; 39(2): 85 doi: 10.1089/jir.2018.0131
|
| 4 |
Naomi Khaing Than Hlaing, Gayatri Nangia, Kyaw Thet Tun, Sithu Lin, Moe Zaw Maung, Khin Thuzar Myint, A. Mi Mi Kyaw, Soe Thiha Maung, Sithu Sein Win, Aung Hlaing Bwa, Bao‐Li Loza, Khin Maung Win, K. Rajender Reddy. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar. Journal of Viral Hepatitis 2019; 26(10): 1186 doi: 10.1111/jvh.13133
|
| 5 |
N. K. T. Hlaing, R. A. Mitrani, S. T. Aung, W. W. Phyo, M. Serper, A. M. M. Kyaw, A. H. Bwa, K. M. Win, K. R. Reddy. Safety and efficacy of sofosbuvir‐based direct‐acting antiviral regimens for hepatitis C virus genotypes 1‐4 and 6 in Myanmar: Real‐world experience. Journal of Viral Hepatitis 2017; 24(11): 927 doi: 10.1111/jvh.12721
|
| 6 |
Magdalena PLUTA, Maria POKORSKA-ŚPIEWAK, Małgorzata ANISZEWSKA, Zbigniew LEWANDOWSKI, Barbara KOWALIK-MIKOŁAJEWSKA, Magdalena MARCZYŃSKA. Pegylated interferon and ribavirin gone but not forgotten in the era of direct-acting antivirals. Minerva Pediatrics 2022; 74(1) doi: 10.23736/S2724-5276.20.05881-8
|
| 7 |
Thi Q. Doan. Hepatitis C in Developing Countries. 2018; : 97 doi: 10.1016/B978-0-12-803233-6.00009-6
|